We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Oxygen Biotherapeutics Announces Plans for Additional Oxycyte® Phase II Clinical Trials
News

Oxygen Biotherapeutics Announces Plans for Additional Oxycyte® Phase II Clinical Trials

Oxygen Biotherapeutics Announces Plans for Additional Oxycyte® Phase II Clinical Trials
News

Oxygen Biotherapeutics Announces Plans for Additional Oxycyte® Phase II Clinical Trials

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Oxygen Biotherapeutics Announces Plans for Additional Oxycyte® Phase II Clinical Trials"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Oxygen Biotherapeutics, Inc. has announced plans to file a Phase II, dose escalation, clinical trial protocol in Switzerland for use of Oxycyte® in traumatic brain injury (TBI). Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier.

The announcement came in a presentation by Chris J. Stern, DBA, company chairman and CEO, at the BIO CEO & Investor Conference in New York. During the presentation, Stern said that the company is in the final stages of preparation to file the protocol in Switzerland. “Depending on the timing of the review process there, we could begin enrolling patients in the second quarter,” said Stern.

In addition, Stern said in the presentation that the company is targeting to have a topical wound care product ready to come to market as early as the end of 2009.
Advertisement